Zhu B T, Bui Q D, Weisz J, Liehr J G
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77555-1031.
Endocrinology. 1994 Nov;135(5):1772-9. doi: 10.1210/endo.135.5.7956900.
As part of an ongoing investigation of the role of metabolic activation of estrogens in the genesis of cancers such as estrogen-induced renal tumors in hamsters, we have 1) determined steroid-17 beta-oxidoreductase activity of microsomes and cytosol prepared from hamster kidney and liver; 2) compared the rates of 2-, 4-, and 16 alpha-hydroxylations of estrone by microsomes from hamster kidney and liver; and 3) determined the rates of inactivation of 2- and 4-hydroxyestrone by catechol-O-methyltransferase from hamster kidney and by purified enzyme. Microsomal steroid-17 beta-oxidoreductase activity in hamster kidney and liver was low and favored the conversion of estrone to estradiol. Cytosolic steroid-17 beta-oxidoreductase activity was only barely detectable in both liver and kidney. Using hepatic microsomes, the rate of 2-hydroxylation of estrone was comparable to that found previously using estradiol as substrate, whereas 4-hydroxylation of estrone was double that of estradiol. Using renal microsomes, the rates of 2- and 4-hydroxylation of estrone were 10- to 20-fold higher than those with estradiol as substrate, and the ratio of 2- to 4-hydroxylation was about 2:1. Fadrozole hydrochloride was an equally good inhibitor of rates of 2- and 4-hydroxylation of estrone (20 microM) by hepatic microsomes (IC50, approximately 25 microM). Corresponding IC50 values with renal microsomes were less than 2 microM, and 2-hydroxylation of estrone was inhibited by Fadrozole hydrochloride up to 15% more than 4-hydroxylation. Treatment of hamsters with estradiol for 2 months decreased rates of 2- and 4-hydroxylation of estrone by renal microsomes by approximately 95%. The rate of conversion of estrone to 16 alpha-hydroxyestrone by hepatic microsomes was 10-20% that of 2-hydroxylation. Renal microsomes catalyzed 16 alpha-hydroxylation of estrone at an even lower rate (approximately 5% of that of 2-hydroxylation). Rates of O-methylation of 2- and 4-hydroxyestrone by hamster kidney cytosol were comparable to those of 2- and 4-hydroxyestradiol. In conclusion, conversion of estrone to its catechol metabolites by microsomes of hamster kidney, a target organ of estrogen-induced carcinogenesis, is quantitatively more important than the conversion to 16 alpha-hydroxyestrone. The findings are consistent with the postulated role of catechol estrogens generated in situ in estrone-induced carcinogenesis.
作为对雌激素代谢活化在诸如仓鼠雌激素诱导的肾肿瘤等癌症发生过程中所起作用的一项正在进行的研究的一部分,我们进行了以下研究:1)测定了从仓鼠肾脏和肝脏制备的微粒体和胞质溶胶的类固醇-17β-氧化还原酶活性;2)比较了仓鼠肾脏和肝脏微粒体对雌酮进行2-、4-和16α-羟基化的速率;3)测定了仓鼠肾脏儿茶酚-O-甲基转移酶和纯化酶对2-和4-羟基雌酮的失活速率。仓鼠肾脏和肝脏中的微粒体类固醇-17β-氧化还原酶活性较低,且有利于雌酮向雌二醇的转化。在肝脏和肾脏中,胞质溶胶类固醇-17β-氧化还原酶活性仅勉强可检测到。使用肝脏微粒体时,雌酮的2-羟基化速率与先前以雌二醇为底物时的速率相当,而雌酮的4-羟基化速率是雌二醇的两倍。使用肾脏微粒体时,雌酮的2-和4-羟基化速率比以雌二醇为底物时高10至20倍,且2-羟基化与4-羟基化的比率约为2:1。盐酸法倔唑是肝脏微粒体对雌酮进行2-和4-羟基化速率(20微摩尔)的同样有效的抑制剂(IC50,约25微摩尔)。肾脏微粒体的相应IC50值小于2微摩尔,且盐酸法倔唑对雌酮2-羟基化的抑制作用比对4-羟基化的抑制作用多高达15%。用雌二醇处理仓鼠2个月可使肾脏微粒体对雌酮的2-和4-羟基化速率降低约95%。肝脏微粒体将雌酮转化为16α-羟基雌酮的速率是2-羟基化速率的10-20%。肾脏微粒体催化雌酮16α-羟基化的速率更低(约为2-羟基化速率的5%)。仓鼠肾脏胞质溶胶对2-和4-羟基雌酮的O-甲基化速率与2-和4-羟基雌二醇的相当。总之,在雌激素诱导致癌作用的靶器官仓鼠肾脏中,微粒体将雌酮转化为其儿茶酚代谢物在数量上比转化为16α-羟基雌酮更重要。这些发现与原位生成的儿茶酚雌激素在雌酮诱导致癌作用中的假定作用一致。